论文部分内容阅读
肿瘤坏死因子相关凋亡诱导配体(tumor necrosis factor-related apoptosis-inducing ligand,TRAIL)为近年来发现的TNF超家族新成员,因其特异性诱导肿瘤细胞凋亡,而对正常细胞无毒性,近年来成为在诱导肿瘤细胞凋亡研究的热点。但随着研究的深入,发现TRAIL对肝细胞的损害及部分肿瘤细胞对TRAIL的耐药限制了其进一步的临床应用。本文将就近年来在逆转肿瘤细胞对TRAIL耐药的策略上做一综述。
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a new member of TNF superfamily discovered in recent years. Because of its specific induction of tumor cell apoptosis, TRAIL is non-toxic to normal cells, In recent years, it has become a hot spot in inducing apoptosis of tumor cells. However, with further research, it is found that the damage of hepatocytes by TRAIL and the resistance of some tumor cells to TRAIL have limited their further clinical application. This article will review recent strategies to reverse TRAIL resistance in tumor cells.